StemCell Therapy

Ibio Inc (IBIO) is near the middle in its industry group according to InvestorsObserver. IBIO gets an overall rating of 57. That means it scores higher than 57 percent of stocks. Ibio Inc gets a 61 rank in the Biotechnology industry. Biotechnology is number 15 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ibio Inc (IBIO) stock has risen 60.53% while the S&P 500 is down -4.94% as of 9:44 AM on Wednesday, Mar 18. IBIO has gained $0.69 from the previous closing price of $1.14 on volume of 5,817,991 shares. Over the past year the S&P 500 is lower by -15.12% while IBIO has gained 103.33%. IBIO lost -$1.35 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Continued here:
Industry Breakdown: Where Does Ibio Inc (IBIO) Stock Fall in the Biotechnology Field? - InvestorsObserver

This entry was posted on March 18, 2020 at 11:48 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |